Recommended

Ph. Eur. Commission updates mAb standards
FDA approves Omisirge cell therapy for severe aplastic anaemia
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
Pfizer $2bn GLP-1 YaoPharma deal
Lilly furthers US onshoring with new manufacturing facility
Europe makes progress in agreeing new pharma legislation
J&J biologics demonstrate potential in multiple myeloma
Moderna expands mRNA drug delivery capabilities
WEBINAR: reflections and future opportunities in pharmaceutical microbiology
CSL invests $1bn in new vaccine manufacturing facility
CHMP recommends two new cancer drugs in Dec 2025 meeting

List view / Grid view

Drug Discovery

 

Drug Discovery and Development
Drug Discovery and Development
article

A new vision of drug discovery and development

18 December 2012 | By D. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute and Allegheny Foundation Professor of Computational and Systems Biology, University of Pittsburgh School of Medicine

The pharmaceutical industry has experienced a decade of turbulence driven by the ‘patent cliff’ as major revenue generators are lost to generic status, coupled to the absence of a sustainable pipeline of drug candidates in development that have a good chance of being approved and launched. It is generally agreed…

What is label-free screening and why use it in drug discovery?
What is label-free screening and why use it in drug discovery?
article

What is label-free screening and why use it in drug discovery?

18 December 2012 | By Matthew A. Cooper and Reena Halai, Institute for Molecular Bioscience, the University of Queensland

In the journey of a molecule from its origins in a compound library to candidate drug status, a large variety of profiling must occur to define activity, selectivity, potency, adverse effects, pharmacology and in vivo efficacy. Advances in biophysical methods that can analyse drug interactions with a molecular target, a…

Drug discovery assays for the histone deacetylase class of enzymes
Drug discovery assays for the histone deacetylase class of enzymes
article

Drug discovery assays for the histone deacetylase class of enzymes

18 December 2012 | By Sheraz Gul and Gesa Witt, European ScreeningPort GmbH

The histone deacetylase (HDAC) class of enzyme are a group of conserved enzymes known for their ability to remove acetyl groups from lysine residues on histone tails. Since aberrant HDAC enzyme expression is observed in various diseases, there is increasing interest in finding small molecules which function as HDAC enzyme…

TAP Biosystems equipment
TAP Biosystems equipment
news

Tecan and TAP Biosystems to automate RAFT™ 3D cell culturing on the Freedom EVO®

30 October 2012 | By kdm communications limited

Tecan and TAP Biosystems, a leading supplier of innovative cell culture systems, have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform. Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D…

article

Biologics: Teamwork pays off in race to expand market for monoclonal antibodies

22 October 2012 | By Bahija Jallal, Executive Vice President, Research & Development, MedImmune

The first biologic drug – infliximab (Remicade) – was launched in 1998 with initial sales of USD 500 million per annum. By 2010, Reuters’ top 10 drugs by sales included five biologics (Remicade, Enbrel, Humira, Avastin and Humira) generating around USD 34 billion in revenue, including USD 7.4 billion from…

Figure 1: Schematic representation of body compartments in physiologically based pharmacokinetic modelling. Abbreviations: Qorgan: Blood flow to organ
Figure 1: Schematic representation of body compartments in physiologically based pharmacokinetic modelling. Abbreviations: Qorgan: Blood flow to organ
article

Physiologicaly based pharmacokinetic modelling of transporters in drug discovery and development

3 September 2012 | By Pradeep Sharma and Katherine Fenner, Global DMPK, AstraZeneca R&D

Physiologically based pharmacokinetic (PBPK) models describe the different compartments (tissues) in the body linked via arterial and venous blood flow (Figure 1). The volume of each tissue and blood flows are available from literature data1-5 and PBPK models have been developed for many species including rat, mouse, dog, pig and…

Man on a phone analysing data and charts on computer screen
Man on a phone analysing data and charts on computer screen
article

Integrating preclinical data into early clinical development

3 September 2012 | By Vikash Sinha, Clinical Pharmacology Leader, Janssen Research and Development

One of the important goals in preclinical and early clinical drug development is to reduce attrition rates and to improve our ability to pick winners and drop potential loser drug candidates. By being able to efficiently translate preclinical data and observations into possible clinical outcomes, one can make the drug…

drug discovery & drug development
drug discovery & drug development
article

The need for proteomic-based biomarkers in the drug development pipeline

10 July 2012 | By Paul C. Guest, Department of Chemical Engineering and Biotechnology, University of Cambridge and Sabine Bahn Department of Chemical Engineering and Biotechnology, University of Cambridge & Department of Neuroscience, Erasmus Medical Centre

Pharmaceutical companies are under increasing pressure to improve their efficiency and returns on drug discovery projects. This is a daunting task considering that the average drug costs approximately one billion US dollars to develop and takes around 12 years from initial discovery to reach the market1. In addition, approximately 70…

article

Discovery chemistry outsourcing

26 April 2012 | By Luigi La Vecchia, Director of the Preparations Laboratories, Novartis Institute for Biomedical Research

In 2002, Novartis decided to create a new research centre in Cambridge, MA. This was accompanied by a significant increase in headcount in medicinal chemistry. Within two years, this resulted in a strongly increased demand for prep-scale synthesis which in turn led to priority issues and to prolonged turnaround times…

article

Outsourcing in early drug discovery: Evolution and opportunities

26 April 2012 | By Jayshree Mistry, Paul Lloyd, Kevin Oliver and Peter North, GlaxoSmithKline R&D and Duncan Judd, Awridian

This article describes the evolution of outsourcing within early drug discovery at GlaxoSmithKline (GSK), specifically for chemistry services applied to developing a compound from the screening hit through lead optimisation. It will touch on different business models, factors to consider when selecting potential CROs, the benefits of outsourcing and CRO…

article

GPCR screening and drug discovery: Challenges and latest trends

26 April 2012 | By Sofia M.A. Martins, João R.C. Trabuco, Gabriel A. Monteiro and Duarte Miguel Prazeres, Institute for Biotechnology and Bioengineering, Instituto Superior Técnico, Technical University of Lisbon

G-protein coupled receptors (GPCRs) are one of the most popular drug targets today. Almost one third of the approved drugs currently available rely on some kind of interaction with these receptors. The annual revenues are around USD 30 billion (109) and the fact that one quarter of the top US…

article

MRI in drug discovery

28 February 2012 | By Peter R. Allegrini, Novartis Institutes for BioMedical Research

MRI is widely used for clinical diagnosis as well as in research areas such as preclinical drug discovery, clinical development and also in therapy monitoring. MRI allows non-invasive acquisition of tomographic images of soft tissue with high resolution and contrast. Furthermore, its ability to assess organ function in a broad…

article

Drug discovery leaders roundtable

13 December 2011 | By Andrew A. Parsons, Vice President Preclinical Drug Development, GlaxoSmithKline and Steve Street, Vice President, Head of Research Centres of Emphasis, Head of WRD Continuous Improvement, Pfizer and William Strohl, Vice President of Biologics Research, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development and Eckhard von Keutz, Senior Vice President, Head Global Early Development, Bayer HealthCare

External economic pressures have been identified as the major driver for the pharmaceutical outsourcing market. Over and above the fiscal advantages of adopting this strategy, what other benefits and indeed risks do you see associated with this approach? Steve Street: We definitely began our out - sourcing efforts based on…